(WKL) Wolters Kluwer - Ratings and Ratios
Health Software, Tax Solutions, Compliance Tools, Legal Research, ESG Platform
Dividends
| Dividend Yield | 2.75% |
| Yield on Cost 5y | 3.81% |
| Yield CAGR 5y | 14.82% |
| Payout Consistency | 97.0% |
| Payout Ratio | 45.8% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 20.9% |
| Value at Risk 5%th | 33.0% |
| Relative Tail Risk | -3.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.14 |
| Alpha | -49.41 |
| CAGR/Max DD | -0.05 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.536 |
| Beta | 0.092 |
| Beta Downside | 0.022 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.83% |
| Mean DD | 10.37% |
| Median DD | 3.93% |
Description: WKL Wolters Kluwer December 17, 2025
Wolters Kluwer N.V. (AS: WKL) is a global provider of professional information, software and services, operating across Health; Tax & Accounting; Financial & Corporate Compliance; Legal & Regulatory; and Corporate Performance & ESG segments. Its offerings span clinical decision-support tools for hospitals and digital-health firms, compliance platforms for tax, audit and legal professionals, and enterprise software that helps corporations meet financial, sustainability and safety reporting requirements. The company, founded in 1836, is headquartered in Alphen aan den Rijn, the Netherlands, and serves customers in Europe, North America, APAC, Africa and beyond.
Key recent metrics: FY 2023 revenue reached roughly €6.2 billion, up about 5 % YoY, with an operating margin near 21 %; the Tax & Accounting segment contributed ~35 % of total revenue, while the Health segment saw double-digit growth driven by accelerated adoption of tele-health and AI-enabled diagnostics. Macro-level drivers include rising regulatory spending worldwide, heightened ESG reporting mandates, and continued digital transformation in both healthcare and financial services, which together underpin demand for Wolters Kluwer’s compliance and performance-management solutions.
For a deeper, data-rich breakdown of these trends, you may find the ValueRay platform a useful resource for further research.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (1.58b TTM) > 0 and > 6% of Revenue (6% = 506.2m TTM) |
| FCFTA 0.23 (>2.0%) and ΔFCFTA 11.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -12.53% (prev -16.99%; Δ 4.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 2.46b > Net Income 1.58b (YES >=105%, WARN >=100%) |
| Net Debt (4.06b) to EBITDA (2.70b) ratio: 1.50 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (231.4m) change vs 12m ago -6.71% (target <= -2.0% for YES) |
| Gross Margin 68.71% (prev 69.16%; Δ -0.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 89.66% (prev 56.03%; Δ 33.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 53.13 (EBITDA TTM 2.70b / Interest Expense TTM 38.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.35
| (A) -0.11 = (Total Current Assets 2.61b - Total Current Liabilities 3.67b) / Total Assets 9.73b |
| (B) 0.14 = Retained Earnings (Balance) 1.36b / Total Assets 9.73b |
| (C) 0.21 = EBIT TTM 2.02b / Avg Total Assets 9.41b |
| (D) 0.15 = Book Value of Equity 1.36b / Total Liabilities 8.85b |
| Total Rating: 1.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.79
| 1. Piotroski 7.0pt |
| 2. FCF Yield 9.34% |
| 3. FCF Margin 26.64% |
| 4. Debt/Equity 5.64 |
| 5. Debt/Ebitda 1.50 |
| 6. ROIC - WACC (= 24.20)% |
| 7. RoE 110.4% |
| 8. Rev. Trend 60.47% |
| 9. EPS Trend -10.55% |
What is the price of WKL shares?
Over the past week, the price has changed by -2.02%, over one month by -3.65%, over three months by -22.51% and over the past year by -43.66%.
Is WKL a buy, sell or hold?
What are the forecasts/targets for the WKL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 138 | 56.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 74.5 | -15.6% |
WKL Fundamental Data Overview December 27, 2025
Market Cap EUR = 20.02b (20.02b EUR * 1.0 EUR.EUR)
P/E Trailing = 18.542
P/E Forward = 15.7729
P/S = 3.2941
P/B = 22.5449
P/EG = 1.7131
Beta = 0.242
Revenue TTM = 8.44b EUR
EBIT TTM = 2.02b EUR
EBITDA TTM = 2.70b EUR
Long Term Debt = 4.45b EUR (from longTermDebt, last quarter)
Short Term Debt = 547.0m EUR (from shortLongTermDebt, last quarter)
Debt = 5.00b EUR (Calculated: Short Term 547.0m + Long Term 4.45b)
Net Debt = 4.06b EUR (from netDebt column, last quarter)
Enterprise Value = 24.08b EUR (20.02b + Debt 5.00b - CCE 942.0m)
Interest Coverage Ratio = 53.13 (Ebit TTM 2.02b / Interest Expense TTM 38.0m)
FCF Yield = 9.34% (FCF TTM 2.25b / Enterprise Value 24.08b)
FCF Margin = 26.64% (FCF TTM 2.25b / Revenue TTM 8.44b)
Net Margin = 18.72% (Net Income TTM 1.58b / Revenue TTM 8.44b)
Gross Margin = 68.71% ((Revenue TTM 8.44b - Cost of Revenue TTM 2.64b) / Revenue TTM)
Gross Margin QoQ = 64.22% (prev 71.49%)
Tobins Q-Ratio = 2.47 (Enterprise Value 24.08b / Total Assets 9.73b)
Interest Expense / Debt = 0.28% (Interest Expense 14.0m / Debt 5.00b)
Taxrate = 21.93% (148.0m / 675.0m)
NOPAT = 1.58b (EBIT 2.02b * (1 - 21.93%))
Current Ratio = 0.71 (Total Current Assets 2.61b / Total Current Liabilities 3.67b)
Debt / Equity = 5.64 (Debt 5.00b / totalStockholderEquity, last quarter 887.0m)
Debt / EBITDA = 1.50 (Net Debt 4.06b / EBITDA 2.70b)
Debt / FCF = 1.81 (Net Debt 4.06b / FCF TTM 2.25b)
Total Stockholder Equity = 1.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.22% (Net Income 1.58b / Total Assets 9.73b)
RoE = 110.4% (Net Income TTM 1.58b / Total Stockholder Equity 1.43b)
RoCE = 34.31% (EBIT 2.02b / Capital Employed (Equity 1.43b + L.T.Debt 4.45b))
RoIC = 29.32% (NOPAT 1.58b / Invested Capital 5.38b)
WACC = 5.12% (E(20.02b)/V(25.02b) * Re(6.35%) + D(5.00b)/V(25.02b) * Rd(0.28%) * (1-Tc(0.22)))
Discount Rate = 6.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.21%
[DCF Debug] Terminal Value 79.58% ; FCFE base≈1.78b ; Y1≈1.95b ; Y5≈2.49b
Fair Price DCF = 191.2 (DCF Value 43.33b / Shares Outstanding 226.6m; 5y FCF grow 11.08% → 3.0% )
EPS Correlation: -10.55 | EPS CAGR: -60.51% | SUE: 0.0 | # QB: 0
Revenue Correlation: 60.47 | Revenue CAGR: 11.27% | SUE: -0.02 | # QB: 0
EPS next Year (2026-12-31): EPS=5.76 | Chg30d=-0.003 | Revisions Net=+2 | Growth EPS=+8.8% | Growth Revenue=+3.3%